TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
This Quarter Return
+8.28%
1 Year Return
-56.28%
3 Year Return
-45.76%
5 Year Return
+44.93%
10 Year Return
–
AUM
$329M
AUM Growth
+$329M
(+31%)
Cap. Flow
+$72.1M
Cap. Flow
% of AUM
21.96%
Top 10 Holdings %
Top 10 Hldgs %
78.01%
Holding
27
New
4
Increased
10
Reduced
4
Closed
5
Top Buys
| 1 |
Quest Diagnostics
DGX
|
$19.4M |
| 2 |
Pacira BioSciences
PCRX
|
$13.2M |
| 3 |
Haemonetics
HAE
|
$12.1M |
| 4 |
Zimmer Biomet
ZBH
|
$10.9M |
| 5 |
Bio-Rad Laboratories Class A
BIO
|
$10.8M |
Top Sells
| 1 |
NVRO
NEVRO CORP.
NVRO
|
$6.94M |
| 2 |
Lantheus
LNTH
|
$6.06M |
| 3 |
Alkermes
ALKS
|
$5.11M |
| 4 |
Service Corp International
SCI
|
$4.82M |
| 5 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
$4.42M |
Sector Composition
| 1 | Healthcare | 88.8% |
| 2 | Industrials | 6.81% |
| 3 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
MDRX
1
DELISTED
Veradigm Inc. Common Stock
MDRX
| $45.7M | 13.9% |
3,925,000
+375,000
| +11% | +$4.37M |
|
2
Medtronic
MDT
$119B
| $41.2M | 12.52% |
420,000
+70,000
| +20% | +$6.86M |
|
|
3
Bio-Rad Laboratories Class A
BIO
$8.06B
| $30.9M | 9.4% |
100,000
+35,000
| +54% | +$10.8M |
|
|
4
Pacira BioSciences
PCRX
$1.2B
| $27M | 8.22% |
625,000
+305,000
| +95% | +$13.2M |
|
|
SRCL
5
DELISTED
Stericycle Inc
SRCL
| $22.4M | 6.8% |
475,000
-35,000
| -7% | -$1.65M |
|
6
AtriCure
ATRC
$1.84B
| $21.2M | 6.44% |
675,000
+250,000
| +59% | +$7.85M |
|
|
7
Lantheus
LNTH
$3.73B
| $20.1M | 6.11% |
730,000
-220,000
| -23% | -$6.06M |
|
|
8
Quest Diagnostics
DGX
$20.3B
| $19.4M | 5.89% |
+188,900
| New | +$19.4M |
|
|
PTLA
9
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $14.4M | 4.38% |
555,000
-170,000
| -23% | -$4.42M |
|
10
Rigel Pharmaceuticals
RIGL
$697M
| $14M | 4.26% |
5,475,000
+175,000
| +3% | +$448K |
|
11
Hologic
HOLX
$14.9B
| $13M | 3.96% |
275,000
+50,000
| +22% | +$2.37M |
|
|
12
Haemonetics
HAE
$2.63B
| $12.1M | 3.67% |
+100,000
| New | +$12.1M |
|
|
13
Zimmer Biomet
ZBH
$21B
| $10.9M | 3.3% |
+90,000
| New | +$10.9M |
|
14
NovoCure
NVCR
$1.38B
| $9.64M | 2.93% |
+150,000
| New | +$9.64M |
|
|
CMD
15
DELISTED
Cantel Medical Corporation
CMD
| $9.11M | 2.77% |
115,000
+85,000
| +283% | +$6.74M |
|
|
CORV
16
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
| $7.44M | 2.26% |
3,350,000
+950,000
| +40% | +$2.11M |
|
|
ISEE
17
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $3.72M | 1.13% |
3,000,000
| – | – |
|
|
STRM
18
DELISTED
Streamline Health Solutions
STRM
| $3.28M | 1% |
2,100,000
+150,000
| +8% | +$234K |
|
|
NVRO
19
DELISTED
NEVRO CORP.
NVRO
| $3.15M | 0.96% |
50,000
-110,000
| -69% | -$6.94M |
|
|
20
Alkermes
ALKS
$4.78B
| – | – |
-140,000
| Closed | -$5.11M |
|
21
Amgen
AMGN
$155B
| – | – |
0
| – | – |
|
|
HIND
22
Vyome Holdings, Inc. Common Stock
HIND
$243M
| – | – |
-2,044,440
| Closed | -$2.94M |
|
|
23
Service Corp International
SCI
$11.1B
| – | – |
-120,000
| Closed | -$4.82M |
|
24
SPDR S&P 500 ETF Trust
SPY
$658B
| – | – |
0
| – | – |
|
25
Thermo Fisher Scientific
TMO
$186B
| – | – |
-10,000
| Closed | -$2.74M |
|